Log In
Wednesday 23rd May 2018

Value-based drug pricing backed

19th September 2008

Conservative shadow health secretary Andrew Lansley has said that pharmaceutical companies should be paid according to the benefits that their drugs bring to patients.

Speaking to the Confederation of British Industry, Mr Lansley called for a partnership between the NHS and the pharmaceutical industry in a bid to make the latest cancer drugs available to patients. He highlighted Johnson & Johnson's risk-sharing deal on Velcade for the treatment of multiple myeloma and Novartis's offer on Lucentis for the treatment of wet age-related macular degeneration.


Share this page


There are no comments for this article, be the first to comment!

Post your comment

Only registered users can comment. Fill in your e-mail address for quick registration.

Your email address:

Your comment will be checked by a Healthcare Today moderator before it is published on the site.

Article Information

Title: Value-based drug pricing backed
Author: Mark Nicholls
Article Id: 8437
Date Added: 19th Sep 2008


Health Service Journal

Recent Related Articles

Energy drinks ban in the UK


Add to scrapbook
Show Comments
Add comment
Find all related articles


Mayden - Innovative cloud-based web development for the healthcare sector
© Mayden Foundation 2018